Mismatch repair deficient colorectal cancer in the era of personalized treatment

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Molecular and genetic subtyping enables individualized cancer therapies with improved efficacy and reduced toxicity.
• A significant subset of colorectal cancer (CRC) exhibits a deficiency in the mismatch repair (MMR) pathway.
• MMR deficiency plays a role in CRC development and influences patient response to common treatments.

Purpose of the Study:

• To describe the MMR deficient phenotype in colorectal cancer.
• To discuss the impact of MMR deficiency on CRC management, including surgery, chemotherapy, and palliative care.
• To explore the potential of exploiting the DNA repair defect in MMR-deficient CRC for novel therapeutic development.

Main Methods:

• Review of existing literature on MMR deficiency in colorectal cancer.
• Analysis of the role of MMR pathway in CRC pathogenesis.
• Discussion of clinical implications for treatment strategies.

Main Results:

• MMR deficiency is a critical determinant in colorectal cancer.
• This deficiency affects treatment responses and management strategies across different stages of CRC.
• The DNA repair defect presents opportunities for innovative therapeutic approaches.

Conclusions:

• MMR deficiency is a crucial factor in colorectal cancer management and treatment.
• Targeting the DNA repair defect in MMR-deficient CRC holds promise for future therapies.
• Individualized treatment strategies based on MMR status can optimize CRC patient outcomes.